Preliminary evidence of motor impairment among polysubstance 3,4-methylenedioxymethamphetamine users with intact neuropsychological functioning.
Neuropsychological disturbances have been reported in association with use of the recreational drug "ecstasy," or 3,4-methylenedioxymethamphetamine (MDMA), but findings have been inconsistent. We performed comprehensive neuropsychological testing examining seven ability domains in 21 MDMA users (MDMA+) and 21 matched control participants (MDMA-). Among MDMA+ participants, median [interquartile range] lifetime MDMA use was 186 [111, 516] doses, with 120 [35-365] days of abstinence. There were no significant group differences in neuropsychological performance, with the exception of the motor speed/dexterity domain in which 43% of MDMA+ were impaired compared with 5% of MDMA- participants (p = .004). Motor impairment differences were not explained by use of other substances and were unrelated to length of abstinence or lifetime number of MDMA doses. Findings provide limited evidence for neuropsychological differences between MDMA+ and MDMA- participants with the exception of motor impairments observed in the MDMA+ group. However, replication of this finding in a larger sample is warranted.
Bousman
Chad A
CA
Department of Psychiatry, University of California San Diego, La Jolla, California 92093, USA.
Cherner
Mariana
M
Emory
Kristen T
KT
Barron
Daniel
D
Grebenstein
Patricia
P
Atkinson
J Hampton
JH
Heaton
Robert K
RK
Grant
Igor
I
D000328:Adult; D019969:Amphetamine-Related Disorders / Q000150:complications* / Q000453:epidemiology; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D008297:Male; D009069:Movement Disorders / Q000453:epidemiology / Q000209:etiology*; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000009:adverse effects*; D009483:Neuropsychological Tests; D013375:Substance Withdrawal Syndrome / Q000150:complications; D055815:Young Adult
D018817:N-Methyl-3,4-methylenedioxyamphetamine